Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats

Brain Research

Volumn 1117, Issue 1, 2006, Pages 206-212

  Owen, Jenny C E ^a   Whitton, Peter S ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Clomipramine; Microdialysis; Paroxetine; Rat; Reboxetine

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; BUDIPINE; CLOMIPRAMINE; DOPAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PAROXETINE; REBOXETINE;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DRUG EFFECT; DRUG TOLERABILITY; FRONTAL CORTEX; MALE; MICRODIALYSIS; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT;

AMANTADINE; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DOPAMINE; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; EXTRACELLULAR FLUID; FRONTAL LOBE; GLUTAMIC ACID; MALE; MICRODIALYSIS; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN UPTAKE INHIBITORS; UP-REGULATION;

EID: 33750108710     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.07.039     Document Type: Article

References (43)

1. Ainsworth K., Smith S.E., Zetterstrom T.S., Pei Q., Franklin M., and Sharp T. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology 140 (2001) 470-477
2. Alter C. Neurotrophins and depression. Trends Pharmacol. Sci. 20 (1999) 59-61
3. Anath J. Treatment-resistant depression. Psychotherapy and Psychosomatic 67 (1998) 61-70
4. Berman R.M., Cappiello A., Annand A., Oren D.A., Heninger G.R., Charney D.S., and Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47 (2000) 351-354
5. Biggs C.S., and Starr M.S. Microdialysis study of the effects of the antiparkinsonian drug budipine on l-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum. Synapse 34 (1999) 36-46
6. Biggs C.S., Pearce B.R., Fowler L.J., and Whitton P.S. Regional effects of sodium valproate on extracellular concentration of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J. Neurochem. 59 (1992) 1702-1708
7. Blier P., and De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15 (1994) 230-236
8. Boyer P.A., Skolnick P., and Fossum L.H. Chronic administration of imipramine and citalopram alters the expression of NMDA subunit mRNA's in mouse brain. J. Mol. Neurosci. 10 (1998) 219-233
9. Carlson J.N., Visker K.E., Nielsen D.M., Keller R.W., and Glick S.D. Chronic antidepressant drug treatment reduces turning behaviour and increases dopamine levels in the medial prefrontal cortex. Brain Res. 707 (1996) 122-126
10. Collu M., Poggiu A.S., Devoto P., and Serra G. Behavioural sensitisation of D2 mesolimbic dopamine receptors in chronic fluoxetine treated rats. Eur. J. Pharmacol. 322 (1997) 123-127
11. D'Aquila P.S., Collu M., Gessa G.L., and Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur. J. Pharmacol. 405 (2000) 365-373
12. Duman R.S. Novel therapeutic approaches beyond the serotonin receptor. Biol. Psychiatry 44 (1998) 324-335
13. Eltze M. Multiple mechanisms of action: the pharmacological profile of budipine. J. Neural Ttransm., Suppl. 56 (1999) 83-105
14. Fisher A., and Starr M.S. Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain. Brain Res. 868 (2000) 268-274
15. Fisher A., Biggs C.S., Eradiri O., and Starr M.S. Dual effects of l-3,4-dihydroxyphenylalanine on aromatic l-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine treated rat: evidence that behaviour is dopamine independent. Neuroscience 95 (2000) 97-111
16. Geoff D.C., and Wine L. Glutamate in schizophrenia: clinical and research implications. Schizophrenia Res. 27 (1997) 157-168
17. Ichikawa J., and Meltzer H.Y. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur. J. Pharmacol. 281 (1995) 255-261
18. Ichikawa J., Kuroki T., and Meltzer H.Y. Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in the rat nucleus accumbens. Eur. J. Pharmacol. 350 (1998) 159-164
19. Layer R.T., Popik P., Olds T., and Skolnick P. Antidepressant-like action of the polyamine site antagonist, eliprodil (SL 82015). Pharmacol. Biochem. Behav. 52 (1995) 615-620
20. Lieberman J.A., Greenhouse J., Hamer R.M., Krishnan K.R., Nemeroff O., Sheenan D.V., Thase M.E., and Keller M.B. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 30 (2005) 445-460
21. Maj J., and Rogoz Z. Synergistic effect of amantadine and imipramine in the forced swimming test. Pol. J. Pharmacol. 52 (2000) 111-114
22. Maj J., Rogoz Z., Skuza G., and Sowinska H. The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test. Pol. J. Pharmacol. 44 (1992) 337-346
23. Millan M.J., Lejeune F., and Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol. 142 (2002) 114-138
24. Mizoguchi K., Yokoo H., Yoshida M., Tanaka T., and Tanaka M. Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and N-methyl-d-aspartate antagonism. Brain Res. 662 (1994) 255-258
25. Nakayama K. Effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 365 (2002) 102-105
26. Nibuya M., Nestler E.J., and Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatment. J. Neurosci. 15 (1995) 7539-7547
27. Nowak G., Ordway G.A., and Paul I.A. Alterations in the N-methyl-d-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 675 (1995) 157-164
28. Owen J.C.E., and Whitton P.S. Effects of amatadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats. Br. J. Pharmacol. 145 (2005) 587-592
29. Page M.E., and Lucki I. Effects of acute and chronic reboxetine treatments on stress-induced monoamine efflux in rat frontal cortex. Neuropsychopharmacology 27 (2002) 237-247
30. Pallotta M., Segieth J., and Whitton P.S. Chronic but not acute clomipramine alters the effect of NMDA receptor regulation of dopamine release in the rat frontal cortex. Neurosci. Lett. 262 (1999) 187-190
31. Pallotta M., Segieth J., and Whitton P.S. Chronic clomipramine administration reverses NMDA-evoked decreases in dopamine release in the raphe nuclei. Brain Res. 823 (1999) 217-220
32. Pallotta M., Segieth J., Sadideen F., and Whitton P.S. Repeated but not acute clomipramine decreases the effect of N-methyl-d-aspartate receptor activation on serotonergic transmission between the raphe nuclei and frontal cortex. Neuropharmacology 41 (2002) 294-300
33. Papp P., and Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. J. Pharmacol. 263 (1994) 1-7
34. Paul I.A., Nowak G., Layer R.T., Popik P., and Skolnick P. Adaptation of the N-methyl-d-aspartate complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther. 269 (1994) 95-102
35. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Co-Ordinates (1982), Academic Press, New York
36. Porter R.H., and Greenamyre J.T. Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochem. 64 (1995) 614-623
37. Rogoz Z., Skuza G., Maj J., and Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 42 (2002) 1024-1030
38. Rogoz Z., Skuza G., Kusmidern M., Woljicowski J., Kor M., and Danysz W. Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioural and pharmacokinetic studies. Pol. Pharmacol. J. 56 (2004) 179-185
39. Skolnick P. Antidepressants for the new millennium. Eur. J. Pharmacol. 375 (1999) 31-40
40. Stryjer R., Strouss R.D., Shaked G., Bar F., Feldman B., Kotler M., Polak L., Rosenscwaig S., and Weizmann A. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int. Clin. Psychopharmacol. 18 (2003) 93-96
41. Trullas R., and Skolnick P. Functional antagonists of the NMDA receptor complex exhibit antidepressant action. Eur. J. Pharmacol. 185 (1990) 1-10
42. Wedzony K., and Golembiowska K. Concomitant administration of MK-801 and desipramine enhances extracellular concentration of dopamine in the rat prefrontal cortex. NeuroReport 5 (1993) 75-77
43. Whitton P.S., Maione S., Biggs C.S., and Fowler L.J. N-methyl-d-aspartate receptors modulate extracellular dopamine concentration and metabolism in rat hippocampus and striatum. Brain Res. 635 (1994) 312-316